Pharming Group N.V. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?

SG&A Cost Management: A Tale of Two Companies

In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Pharming Group N.V. and Viridian Therapeutics, Inc. have demonstrated contrasting approaches to SG&A cost management.

Pharming Group N.V. has seen a significant increase in SG&A expenses, peaking in 2022 with a 1,318% rise from 2014. This upward trend suggests a strategic investment in administrative capabilities and market expansion. In contrast, Viridian Therapeutics, Inc. has maintained a more conservative approach, with a 22% increase in SG&A expenses over the same period, indicating a focus on cost efficiency.

As of 2023, both companies have shown a convergence in their SG&A expenses, with Viridian's costs nearing those of Pharming. This shift could signal a change in strategy or market conditions, making it a pivotal year for both companies.